Clinical, histological and molecular reversibility of zidovudine myopathy

Journal of the Neurological Sciences

Volumn 159, Issue 2, 1998, Pages 226-228

  Masanés, Ferran ^a   Barrientos, Antoni ^a   Cebrián, Mireia ^a   Pedrol, Enric ^a   Miró, Oscar ^a   Casademont, Jordi ^a   Grau, Josep M ^a  

^a Research Unit   (Spain)

Author keywords

Mitochondrial toxicity; Molecular studies; Toxic myopathy; Zidovudine

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MITOCHONDRIAL MYOPATHY; MUSCLE BIOPSY; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL MYOPATHIES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0032516834     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00151-8     Document Type: Article

References (12)

1. Arnaudo E., Dalakas M., Shanske S.et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 337:1991;508-510.
2. Casademont J., Barrientos A., Grau J.M.et al. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain. 119:1996;1357-1364.
3. Chariot P., Gherardi R. Myopathy and HIV infection. Curr Opin Rheumatol. 7:1995;497-502.
4. Dalakas M.C., Illa I., Pezeshkpour G.H.et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 322:1990;1098-1105.
5. Dalakas M.C., Kieburtz K., Grau J.M.et al. HIV or zidovudine myopathy? (letters). Neurology. 44:1994;360-363.
6. Grau J.M., Masanés F., Pedrol E.et al. HIV-1 infection and myopathy. Clinical relevance of zidovudine therapy. Ann Neurol. 34:1993;206-211.
7. Jay Ch., Ropka M., Dalakas M.C. The drugs 2′,3′-dideoxynosine (ddI) and 2′,3′-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy. J Acquir Immune Defic Syndr. 7:1994;630-631.
8. Lewis W., Dalakas M.C. Mitochondrial toxicity of antiretroviral drugs. Nature Med. 1:1995;417-422.
9. Lewis W., Gonzalez B., Chomyn A., Papoian T. Zidovudine induces molecular, biochemical and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest. 89:1992;1354-1360.
10. Miró O., Pedrol E., Cebrián E.et al. Skeletal muscle studies in patients with HIV-related wasting syndrome. J Neurol Sci. 150:1997;153-159.
11. Simpson D.M., Citak K.A., Godfrey E., Godbold J., Wolfe D.E. Myopathies associated with human immunodeficiency virus and zidovudine: Can their effects be distinguished? Neurology. 43:1993;971-976.
12. Urbano-Marquéz A., Estruch R., Navarro F.et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 320:1989;409-415.